Navigation Links
BioMS Medical Announces 2009 Year End Results
Date:3/16/2010

(1,343) ------------ ------------ Foreign exchange gain (loss) on cash and cash equivalents held in foreign currency (134) 3,698 ------------ ------------ (Decrease) increase in cash and cash equivalents (39,052) 52,398 Cash and cash equivalents - Beginning of year 87,826 35,428 ------------ ------------ Cash and cash equivalents - End of year 48,774 87,826 ------------ ------------ ------------ ------------ Cash and cash equivalents consists of Bank accounts 14,855 610 Interest bearing deposits and securities 33,919 87,216 ------------ ------------ 48,774 87,826 ------------ ------------ ------------ ------------

SOURCE BioMS Medical Corp.

Back to top
'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
2. Spectral diagnostics Raises $14 million and enters into strategic collaboration with BioMS Medical to commercialize treatment for sepsis
3. BioMS Medical provides corporate update
4. BioMS Medical Announces Third Quarter 2009 Results
5. BioMS Medical announces second quarter 2009 results
6. BioMS Medical to present at the 2009 Symposium for the Canadian Society for Pharmaceutical Sciences
7. BioMS Medical to participate in panel session at Bio International Convention 2009
8. BioMS Medical Announces First quarter 2009 results
9. BioMS Medical to present at Alberta Economic Forum in Geneva
10. BioMS Medical to present at BioFinance 2009
11. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014 Based on the ... surgical imaging market is dominated by four major ... imaging market. These players include GE Healthcare (U.K.), ... (Germany). , Full Report Copy at ... Healthcare can be attributed to its strong product ...
(Date:12/17/2014)... December 17, 2014 Ipsen Biopharmaceuticals, ... IPN; ADR: IPSEY), today announced that ... as Somatuline®) was approved by the U.S. Food ... gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with ... metastatic disease to improve progression-free survival (PFS). , ...
(Date:12/17/2014)... December 17, 2014 Xeno Diagnostics ... following its most recent COLA inspection. Xeno has ... a national healthcare accreditation organization. Accreditation is earned ... quality in day-to-day operations, demonstrate continued accuracy in ... rigorous on-site laboratory survey. , While ...
(Date:12/17/2014)... Dec. 16, 2014  Vermillion, Inc. (NASDAQ: ... disease, today announced the next step in its expanded ... solutions provider with the naming of current Chief Operating ... Executive Officer, while current Chairman of the Board and ... as Chairman. These changes are effective January 1, 2015. ...
Breaking Biology Technology:Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4
... start-up, CEOs, business development executives, and service providers from ... ... the globe, MASSAPEQUA, N.Y. and CLEVELAND, April 11 ... Corporation, the Cleveland-based bioscience business,formation, recruitment, and acceleration initiative, are ...
... DIEGO, California, April 11 , - Newly ... -, Ortho Biotech Oncology Research & Development ... & Development, L.L.C., will announce,results from studies of ... the American Association for Cancer Research (AACR),2008 Annual ...
... Biopure,Corporation (Nasdaq: BPUR ) announced today ... Regulatory Agency (MHRA) has found the,company,s Pennsylvania ... the principles and guidelines of good manufacturing ... company received confirmation,that it has responded successfully ...
Cached Biology Technology:IBF Conferences Inc*International Business Forum and BioEnterprise Corporation present the 2nd Annual Global Healthcare Investing Conference 2IBF Conferences Inc*International Business Forum and BioEnterprise Corporation present the 2nd Annual Global Healthcare Investing Conference 3Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology R&D Assets 2Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology R&D Assets 3Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology R&D Assets 4Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology R&D Assets 5Biopure Operations Compliant With U.K. Manufacturing Guidelines 2Biopure Operations Compliant With U.K. Manufacturing Guidelines 3
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a leading ... that its DigitalPersona ® Pro Enterprise software ... been deployed throughout First Bank branch locations in ... South Carolina and Virginia. First Bank, a ... Southern Pines, North Carolina , selected the ...
(Date:12/3/2014)... 2014 As part of our commitment to ... pleased to announce the release of a new reader ... the workforce data that they need. The ... by existing readers. Many such devices have serious shortcomings ... technology. Older models force users to navigate numerous complicated ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2
... increasingly turning to a slow-release form of a powerful painkiller ... warn. The trend is raising alarm as the number of ... opioid 100 times more potent than morphine, rises. , Addicts ... of fentanyl through the skin into the bloodstream over the ...
... on a promising new vaccine against a pre-cancerous cervical ... non-invasive cervical cancer, according to a study presented today ... Frontiers in Cancer Prevention Research meeting in Baltimore. ... originally published in early October, confirmed the vaccine's efficacy ...
... will provide valuable information for assessing environmental hazards caused ... Sciences (NIEHS), one of the National Institutes of Health, ... to public health and safety workers on contaminants in ... demographic information for local populations. , The ...
Cached Biology News:Prescription pain patch abuse blamed for increase in deaths 2Prescription pain patch abuse blamed for increase in deaths 3Updated data on novel HPV vaccine confirms efficacy in large population 2FDA approves child-friendly AIDS medicine 2
...
Sterile detoxified 10% bovine serum albumin (BSA) in Iscoves MDM. This BSA has been selected to support the optimal colony growth of human hematopoietic progenitor cells in methylcellulose-based medi...
... A full-featured high-performance ICP-MS system designed for ... interface, Omega II off-axis ion lens, true ... 7500a can handle the widest range of ... the 7500a now includes as standard Agilents ...
... to the DH-2000, except that it uses a ... wavelength range and comes with a shutter (controlled ... 5 Hz) The DH-2000 Deuterium Tungsten ... deuterium and tungsten halogen light sources in a ...
Biology Products: